KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Non-Current Deffered Revenue (2017 - 2025)

Arbutus Biopharma's Non-Current Deffered Revenue history spans 9 years, with the latest figure at $2.9 million for Q1 2025.

  • For Q1 2025, Non-Current Deffered Revenue changed N/A year-over-year to $2.9 million; the TTM value through Mar 2025 reached $2.9 million, changed N/A, while the annual FY2024 figure was $2.9 million, N/A changed from the prior year.
  • Non-Current Deffered Revenue for Q1 2025 was $2.9 million at Arbutus Biopharma, roughly flat from $2.9 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $10.6 million in Q3 2022 and bottomed at $2.9 million in Q4 2024.
  • The 3-year median for Non-Current Deffered Revenue is $4.4 million (2022), against an average of $5.6 million.